The effects of recombinant interferon gamma (rIFNy) on the in vitro growth of adherent synovial fibroblast-like cells from patients with rheumatoid arthritis (RA) 
Interferon gamma (IFNy) has been shown to have antiproliferative, immunomodulatory, and antiviral properties.1-3 The ability of IFNy to induce and enhance the expression of class II major histocompatibility complex antigens on various types of cells is generally believed to be a factor in the pathogenesis of autoimmune disorders such as rheumatoid arthritis (RA).3 4 Recent clinical investigations have shown some efficacy of recombinant IFNy (rIFNy) in the treatment of RA.i Moreover, a number of reports have shown diminished production of IFNy by peripheral blood or synovial fluid lymphocytes from patients with RA,8-3 and the presence of only low concentrations of IFNy in rheumatoid synovial fluids and tissues,'l-5 though contradictory results have also been reported. '6 17 One of the features of RA is the hyperplasia of synovial lining cells and fibroblasts associated with the infiltration of lymphocytes and monocytes/macrophages into affected joints. Inflamed tissues of RA synovium release potent interleukin-l (IL-1) activity,1820 which in turn activates the synovial cells to generate large amounts of tissue degrading mediators, such as collagenase and prostaglandins.2' 22 The role of IFNy in relation to these aspects of RA, however, has not been fully investigated.
This study was designed to investigate the influence of rIFNy on the in vitro proliferation of adherent synovial fibroblast-like cells from patients with RA and the release of prostaTsukada, Haruaki Warabi, Shoji Uchida, glandins and collagenase from these cells stimulated with recombinant interleukin-l,B (rIL-1I3).
The results show the inhibitory effects of rIFNy on both cell proliferation and the rIL-1l3 induced release of prostaglandin and collagenase activity. These results suggest a further aspect of the regulatory role of IFNy in chronic inflammatory disease.
Materials and methods

SOURCE AND PREPARATION OF ADHERENT SYNOVIAL CELLS
Specimens of synovium were obtained at the time of synovectomy from the knee or hip joint of nine patients with classical or definite RA according to the American Rheumatism Association criteria.23 Patients who were taking more than 3 mg/day of prednisolone or 300 mg/day of D-penicillamine were excluded from the study. Adherent synovial cells were prepared from the synovium specimens essentially as has been described previously.24 25 Effect ofinterferon gamma on cultured synovial cellsfrom patients with RA activity except for one sample (patient 6) (table  2) . On the other hand, 0-3 ng/ml of rIL-1l clearly induced the release ofcollagenase activity in all instances. This rIL-1, induced release of collagenase activity was effectively reduced by either 102 or 104 U/ml of rIFNy (table 2) .
Discussion
This study shows some of the regulatory effects of IFNy on the growth and functions of adherent synovial fibroblast-like cells from patients with RA by using IFNy derived from recombinant DNA: rIFNy inhibited not only cell proliferation in most samples, irrespective of their level of prostaglandin synthesis, but also the rIL-fI induced prostaglandin E2 release from all these cell samples. In addition, it also reduced the rIL-113 induced collaganese release from these synovial cells. This is the first demonstration of the inhibitory effect ofrIFNy on the growth ofrheumatoid synovial fibroblast-like cells, although there are a few reports which show the antiproliferative effects of rIFNy against dermal fibroblasts established from skin explants,28 and transformed fibroblastic cell lines.3' In contrast with these results, Brinckerhoff and Guyre reported that rIFNy increased the proliferation of synovial fibroblasts in culture. 25 One possible explanation of the various results may be differences of cell properties and cell population in culture, which depend on cell-donor individuality, passage number, and so on. Even in our own preliminary tests, both WI-38, a well known fibroblastic cell line resistant to IFNy,3' and one out of every two synovial cell samples obtained from patients with non-inflammatory joint diseases, showed slight increases in proliferation in response to low doses of rIFNy (unpublished observation). All the samples of adherent synovial fibroblast-like cells in this study were obtained from patients with classical or definite rheumatoid arthritis,23 and six of nine were clearly sensitive to the antiproliferative effect of rIFNy when used at the second to fourth passages. Thus we conclude that at least for rheumatoid synovial fibroblast-like cells rIFNy acts as a decelerator of cell proliferation in most instances. Nevertheless, the extent of the inhibition of proliferation by rIFNy was variable from sample to sample in our study.
For a more precise analysis of these variations and of the discrepancy between studies further experiments with isolated subpopulations of adherent synovial cells would be needed.
Blocking of rIL-113 induced prostaglandin E2 release by rIFNy has been reported for human peripheral monocytes.32 Our study shows the inhibition by rIFNy of rIL-l induced prostaglandin release from rheumatoid synovial fibroblast-like cells. On the other hand, Amento et al reported an example in which rIFNy influenced neither the basal release nor the crude monokine preparation-stimulated release of prostaglandin E2 from cultured synovial cells collected from a patient with RA. 26 The discrepancy between their results and ours might be attributable to differences between the stimuli used, because the regulatory effects of rIFNy on prostanoid release from human monocytes or murine macrophages have been shown to depend largely on the nature ofthe stimulus. [32] [33] [34] [35] Alternatively, the discrepancy might again be explained by differences in the properties of synovial cells, perhaps due to differences in the inflammatory condition of cell donors, because the extent of the inhibition of rIL-lI1 stimulated prostaglandin E2 release by rIFNy has been shown to correlate negatively with the erythrocyte sedimentation rate of cell donor patients (unpublished observation).
Interleukin-1 has been shown to activate phospholipase A2, generally believed to be a rate limiting enzyme in the generation of prostanoids, in rat fibroblasts36 and rabbit chondrocytes. 37 
